findmyKOL
Clinical trialNCT02921022Active, not recruitingInterventional

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

SponsorMemorial Sloan Kettering Cancer CenterEnrollment110Advanced Pancreatic Ductal AdenocarcinomaPancreatic Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational. The Food and Drug Administration (FDA) has not approved the marketing or sale of PEGPH20, but have authorized its use in research studies with humans. PEGPH20 could shrink the cancer but it also can cause side effects. PEGPH20 is an enzyme that breaks down a specific tissue component called hyaluronan produced by some tumors. Pancreatic tumors often have a large amount of hyaluronan. The removal of hyaluronan from tumors may decrease tumor growth.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Hartford Healthcare Cancer Institute @ Hartford Hospital

    Hartford, Connecticut, United States

  • Miami Cancer Institute

    Miami, Florida, United States

  • Memorial Sloan Kettering Basking Ridge

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Monmouth

    Middletown, New Jersey, United States

  • Memorial Sloan Kettering Bergen

    Montvale, New Jersey, United States

  • Memorial Sloan Kettering Commack

    Commack, New York, United States

  • Memorial Sloan Kettering Westchester

    Harrison, New York, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, United States

  • Memorial Sloan Kettering Nassau

    Uniondale, New York, United States

  • Lehigh Valley Health Network

    Allentown, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Gemcitabine →Paclitaxel →PEGPH20
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Oct 2016
Primary completion
31 Oct 2026
Completion
31 Oct 2026
Last update posted
26 Nov 2025
Registered enrollment
110
Registry id
NCT02921022
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.